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Available online 23 January 2016AbstractBackground: Refractory Crohn's disease, especially when complicated by complex perianal fistula, seriously reduces the patients' quality of life.
Preclinical and clinical studies indicate stem cells may be a promising therapy for refractory Crohn's disease.
Objective: To systematically review evidence on clinical efficacy and safety of stem cells in refractory Crohn's disease.
Methods: A detailed search was performed to identify randomized controlled trials (RCT), systematic reviews of RCTs or high-quality non-
RCTs published before September 2015 in the Cochrane Library, PubMed, Medline, EMBASE, and the ISI Web of Knowledge databases.
Search terms included: MSC (mesenchymal stem cell), stem cells, HSC (hematopoietic stem cell), IBD (inflammatory bowel disease), CD
(Crohn's disease), UC (ulcerative colitis). Two authors independently extracted data for analysis using predefined selection criteria and quality
indicators. Trials were also retrieved from the website of www.Clinicaltrials.gov.
Results: 18 of the 225 articles identified met the inclusion criteria. However, there were only two studies that had control groups. Therefore, a
brief qualitative analysis of the evidence was considered to be more adequate. It seems stem cells can reduce Crohn's Disease Activity Index
(CDAI) and help alleviate CD symptoms. Moreover, the incidence of serious adverse events caused by stem cell transplantation was very low
(1.75%, 7/400).
Conclusions: Stem cell therapy for CD is very promising, but large, multicenter and randomized clinical trials are needed to further support their
therapeutic benefits.
Copyright © 2016, Shanghai Hengrun Biomedical Technology Research Institute. Publishing Services By Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The etiology of Crohn's disease (CD) is still not well un-
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under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4mucosa and the host immune system has been implicated in the
pathogenesis of CD [1]. Perianal fistula is the most notorious
complication of CD, which is formidable for both patients and
clinicians, as there are around 25e30% patients having no other
alternative choices but accepting surgery [2]. The past two
decades have seen an explosion of scientific and clinical interest
in stem cell transplantation for a variety of diseases including
CD. There are several kinds of candidate stem cells with po-
tential application for CD, such as hematopoietic stem cells
(HSCs), amniotic fluid stem cells (AFSCs), induced pluripotent
stem cells (iPSCs) and mesenchymal stem cells (MSCs) [3].h Institute. Publishing Services By Elsevier B.V. This is an open access article
.0/).
Table 1
Pre-specified eligibility criteria.
Participants Interventions Comparison Outcomes Study types
CD patients, age 18yr
Refractory to or unsuitable
for current available therapies
Autologous/Allogeneic
MSCs
Autologous/Allogeneic
HSCs
Self-control or placebo controls
using fibrin glue or routine therapies
Clinical/Endoscopic
remission/response (defined by CADI)
perianal fistulas healing/closure SAEs
should be included
RCTs/Systematic
reviews of
RCTs/high-quality
Non-RCTs
CD: Crohn's disease; yr: year; MSCs: mesenchymal stem cells; HSCs: hematopoietic stem cells; CDAI: Crohn's Disease Activity Index; SAEs: serious adverse
events; RCT: randomized controlled trials.
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trials [4]. Thus, the present review will focus on published
clinical trials using HSCs and MSCs.
Accumulating literature has showed MSCs and HSCs may
be beneficial for CD patients. We searched all studies available
to evaluate clinical efficacy and safety of stem cells in severe
refractory CD. Located in bone marrow, HSCs can give rise to
all blood cells and transplanted HSCs can reconstitute the
hematopoietic system of the hosts [5]. HSCs transplantation is
widely considered to be a potential therapy for severe auto-
immune diseases [6]. With the synergistic effect of adhesion
molecules and platelets, HSCs are able to home to the injured
tissues [7].
Originally isolated from bone marrow, MSCs can also be
isolated from a variety of other sources such as placenta,
umbilical cord, adipose tissue, teeth and menstrual fluid [8].
Bone marrow-derived MSCs are best characterized for their
biological functions and most widely used for immunoregu-
lation and regenerative cell therapy [9e11]. Like HSCs, they
are also capable of migrating to injured tissues. In contrast to
HSCs, MSCs transplantation do not induce graft-versus-host-
disease (GVHD) and have even been used to treat GVHD [12].
2. Methods2.1. Research question and objectivesThis review aimed to answer the following question: Is
autologous/allogeneic stem cell transplantation a safe and
effective treatment for refractory CD? The primary objectives
were to assess whether patients receiving stem cells trans-
plantation achieved:
1. any response to the stem cell-based therapies;
2. any alleviation in both clinical symptoms and endoscopic
findings of CD;
The secondary objectives were to assess whether the fre-
quency and nature of adverse events was acceptable.2.2. Data sourcesThe search strategy was developed in accordance with the
Center for Reviews and Dissemination's Guidance for Sys-
tematic Reviews in Health Care [13] and the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [14].The Cochrane Library, PubMed, Medline, EMBASE, and
the ISI Web of Knowledge databases were searched for papers
published from the data of the database set-up to September
2015 using the following key words: MSC (mesenchymal stem
cell), stem cells, IBD (inflammatory bowel disease), CD
(Crohn's disease), UC (ulcerative colitis), and combined words
using Boolean logic (AND, OR). We also searched Clinical-
Trials.gov for relevant clinical studies. To increase sensitivity,
no restrictions were placed on study/trial/review type.2.3. Eligibility criteria for the review (PICOS elements)Detailed information on the participants, interventions,
comparisons, and outcomes to be included was provided in
Table 1, as advocated by the 2009 Centre for Reviews and
Dissemination handbook.2.4. Study selectionTwo investigators (LY and NY) undertook the initial screen
of titles and abstracts. Any disagreement about selection de-
cisions was then discussed until concordance was reached.
Full manuscripts of papers identified as potentially relevant
were reviewed independently by the same two authors ac-
cording to the pre-specified eligibility criteria showed in Table
1. Duplicate articles and those published in a language other
than English were excluded. The selection process was
showed in Fig. 1.2.5. Critical evaluation and quality assessmentResearches may vary considerably in methodology in the
design or conduct of a study, obscuring the benefit/harm of an
intervention. Each study included in a review must therefore
undergo a quality assessment process. In accordance with the
Cochrane Reviewers' Handbook and the Newcastle-Ottawa
[15], each literature was assessed by the same investigators.
Disagreement was resolved according to the pre-defined
criteria.2.6. Results and data synthesisData extraction sheets were completed for each study.
Quantitative data analyses were performed for eligible studies
with adequate data; due to study heterogeneity and the small
number of incorporated studies, meta-analysis was considered
inappropriate for this review. Therefore, a brief qualitative
Fig. 1. A PRISMA diagram outlining the search strategy and study selection.
23L. Ye et al. / Journal of Cellular Immunotherapy 2 (2016) 21e27analysis of the evidence was presented in narrative form
shown in Tables 2e4.
3. Review of objectives3.1. Do patients response to the stem cell-based
therapies?As shown in Tables 2e4, a total of 18 articles were eligible
for the qualitative analyses. To be more specific, there were
6 clinical trials using HSCs and 12 using MSCs respectively.
Clinical response was defined as a decrease in Crohn's Disease
Activity Index (CDAI) >100. Endoscopic improvement referred
to a decrease of Crohn's disease endoscopic index of severity
greater than 5, or a Crohn's disease endoscopic index of severity
of less than 3. Considering some patients have developed
perianal fistulas, the combined measurement of clinical
response was defined as fistula closure. Totally there were 483
patients (Tables 2e4) with 400 evaluable CD patients.
The data concerning luminal CD was limited. Five avail-
able studies had 45 CD patients, with improvement in clinicalsigns in 42. The results indicated a promising role of MSCs in
CD therapy. As regarding the local treatment of perianal CD,
similar satisfactory results have been published. Tow recently
published studies [31,32], one study showed that a complete
closure was achieved in 27 out of 33 patients after the final
injection of ASCs [32]. However, a study conducted by Her-
reros et al. [33] including 200 participants stated that ASCs
alone or in combination with fibrin glue was equivalent to
fibrin glue alone.3.2. Is there any remission in signs or symptoms of
Crohn's disease?Of the six studies examining the efficacy of HSCs, the re-
sults were encouraging. Among 66 patients, 57 CD patients
achieved complete remission as indicated by physical exami-
nation, CDAI level (CDAI < 150), bowel ultrasound sonog-
raphy and/or radiological exam [16e21]. HSCs
transplantation seemed to be superior to MSCs transplantation
in terms of remission rate (86.36% (57/66) vs 44.90% (154/
343)). However, due to the heterogeneity of the studies,
Table 2
Hemapoietic stem cells transplantation studies in Crohn's disease.
Study ID Participants Procedure Remission (number of
patients, time of evaluation)
SAEs Recurrence (number of
patients, time of evaluation)
Oyama et al. [16] 12 Autologous HSCs Clinical:11 (12 m) None 1 (15 m)
Burt et al. [17] 24 Autologous HSCs Clinical:24 (6e12 m) 1SAEs not related 9% (12 m)
37% (24 m)
43% (36 m)
61% (48 m)
81% (60 m)
Cassionotti et al. [18] 10 Autologous HSCs Clinical:10 (3 m)
Endoscopic:5 (3 m)
None 20% (12 m)
50% (24 m)
60% (36 m)
70% (48 m)
70% (60 m)
Hasselblatt et al. [19] 12 Autologous HSCs Clinical:5 (6 m)
Endoscopic:5 (6 m)
4SAES related
(fever, renal failure)
7 (37.2 m)
Lopez-cubero et al. [20] 6 (5 evaluable) Allogeneic HSCs Clinical:4 (4.5e15.3 yr) 1SAEs related septicemia 1 (1.5 yr)
Hommes et al. [21] 3 Autologous HSCs Clinical:3 (5e6 yr) None 1 (2 yr)
HSCs: hematopoietic stem cells; m: month; yr: year; SAEs: serious adverse events.
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with. What's more, there were few patients receiving HSCs
transplantation. On the contract, there were 2 multicenter,
randomized and double-blinded trials that evaluated the effi-
cacy of MSCs [28,33].
Preparation of MSCs is more easy and cheaper than that of
HSCs, which needs leukapheresis. In addition, no donor-
recipient matching is required for on-the-shelf MSCs from
donors (such as Prochymal™) [22], which is in contract to
HSCs, for it may cause GVHD after transplantation.3.3. Whether adverse events are acceptable?Each study evaluated the safety of the treatment and found
that the incidence of serious adverse events (SAEs) was low.
Only 3 studies reported several cases of SAEs (Tables 2e4).
Hasselblatt et al. [19] reported 4 individuals who developed
SAEs during stem cell mobilization. Of which, one patient
suffered prolonged neutropenic fever and reversible acute
renal failure as well as vaginal bleeding. Lopez-cubero et al.
[20] recorded 1 case of SAEs. During the long-term follow-up
period (4.5e15.3 yr), 1 patient developed septicemia whichTable 3
Mesenchymal stem cell transplantation studies in luminal Crohn's diseases.
Study ID Participants Procedure Respons
patients,
Onken et al. [22] 10 (9 evaluable) Prochymal™ Clinical:
Duijvestein et al. [23] 10 (6 evaluable) Autologous BMMSCs Clinical:
Endosco
Liang et al. [24] 7 (4CD/3UC) Allogeneic
BMMSCs/UC-MSCs
Clinical:
Endosco
Forbes et al. [25] 16 (15 evaluable) Allogeneic BMMSCs Clinical:
Endosco
Lazebnik et al. [26] 50 (11CD/39UC) Allogeneic BMMSCs Clinical:
39/0 (4e
CD: Crohn's disease; UC: ulcerative colitis; BMMSCs: Bone marrow-derived MSC
mesenchymal stem cells from marrow of screened, healthy volunteers; SAES: ser
d: day; w: week; m: month.was considered to be not related to stem cell therapy. In
another study reported by De la Portilla et al. [30], there were
2 cases of SAEs, which were “pyrexia” and “perianal
abscess”respectively. Overall, the incidence of SAEs was low.
4. Discussion
Up to now, mechanisms for stem cells in treating CD are
still not well understood. Stem cells may suppress the immune
reaction in injured tissues and differentiate into epithelia cells
to promote tissue healing. However, what happens during the
differentiation process remains mysterious. In the present re-
view, we included 6 and 12 trials using HSCs and MSCs
respectively. Despite variations in dosage, timing, and fre-
quency of administration, stem cells seemed to significantly
benefit the patients with refractory CD in terms of both pri-
mary and secondary endpoints. These results were very
encouraging.
Inflammatory bowel diseases include UC and CD. Though
they share similar pathologic and epidemiological features, the
clinical manifestations differ from each other [34]. Unlike UC,
CD causes intestinal transmural inflammation (ulceration) ande/Remission (number of
time of evaluation)
SAEs Recurrence (number of
patients, time of evaluation)
9/3 (14 d) 1SAES unrelated NA
3/0 (6 w)
pic:2/0 (6 w)
None NA
7/3 (3 m)
pic:3/0 (3e5 m)
None 2 (6e7 m)
12/8 (42 d)
pic:7/0 (42 d)
1SAES unrelated NA
11/0 (4e8 m, CD)
8 m, UC)
NA NA
s; UC-MSCs: umbilical cord-derived MSCs; Prochymal™: Ex vivo cultured
ious adverse events; NA: Not available.
Table 4
Mesenchymal stem cell transplantation studies in perianal Crohn's diseases.
Study ID Participants Procedure Response/Closure (number of
patients, time of evaluation)
SAEs Recurrence (number of
patients, time of evaluation)
Garcia-Olmo et al [27] 5 (4 evaluable) Autologous ASCs 8 Fistulas in 4:2/6 (8 w) None NA
Garcia-Olmo et al [28] 49 (14CD) Autologous
Group A:25 (7CD)
ASCs þ Fg
Group B:24 (7CD)
Fg
Group A:NA/1 (7CD, 8 w)
Group B:2/5 (7CD, 8 w)
None Group B:3 (12 m)
Data for CD:NA
Ciccocioppo et al. [29] 12 (10 evaluable) Autologous BMMSCs 3/7 (12 m) None None (12 m)
De la Portilla et al. [30] 24 (22 evaluable) Allogeneic ASCs 23 Fistulas in 22:5/18 (6 m) 2SAES
Pyrexia
Perianal abscess
NA
Cho et al. [31] 10 Autologous ASCs 1/3 (2 m) None 3 (8 m)
Lee et al. [32] 33 Autologous ASCs 5/27 (2 m) None 3 (12 m)
Herreros et al. [33] 200 Autologous
Group A: ASCs
Group B: ASCs þ Fg
Group C: Fg
Group A: NA/25 (12 w)
Group B: NA/26 (12 w)
Group C: NA/22 (12 w)
None NA
CD: Crohn's disease; ASCs: Adipose-derived MSCs; Fg: Fibrin glue; SAES: serious adverse events; NA: Not available; w: week; m: month.
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the global incidence and prevalence of CD are increasing [35].
To date, much progress has been made in the pharmacological
therapy for CD [36]. CD therapy is based on a so-called step-
up approach. 5-Aminosalicylates remain a mainstay of treating
first-episode CD. If it failed, patients would be given by glu-
cocorticoids to achieve rapid symptom relief. For further
therapy, glucocorticoids would be followed by methotrexate or
acetazolamide or 6-MP or cyclosporine follow to gain long-
term disease control [37]. For patients with severe CD who
fail corticosteroids and immunosuppressor such as metho-
trexate, then biological agents are a viable alternative. They
target specific molecules. Infliximab, one of anti-TNF agents,
is a chimeric monoclonal antibody directed against the proin-
flammatory cytokine tumor necrosis factor-a, and has been
approved by the US Food and Drug Administration for use in
moderate to severe CD. Anti-adhesion molecules represent a
new promising immunomodulatory therapy in CD. Vedolizu-
mab is a monoclonal antibody, blocking the pathway of
mucosal addressin cell adhesion molecule-1, was approved in
May 2014 for treating CD [38]. The ultimate goal for CD
therapy is to gain sustained clinical and endoscopic remission
[39]. Nevertheless, there are still about half of CD patients who
do not response to pharmacological therapy and have to receive
intestinal resection in about 10 years after CD onset [40].
Stem cells can home to the damaged tissues and differen-
tiate into specific cells to help restore tissue function or
regulate host immune function through an army of cytokine
and signaling molecules [41e43]. Before HSC transplantation,Table 5
Large ongoing Phase III trials using stem cells for perianal Crohn's diseases.
Trial code Condition Sponsor Status
NCT0154157 Perianal fistula Tigenix Active, no
NCT00482092 Perianal fistula Osiris Therapeutics Active, no
ASCs: Adipose-derived MSCs; Source: Clinicaltrials.gov.patients need to undergo a high-dose immune ablation regimen
to eliminate T-lymphocytes and memory T cells. After
retransfusion of HSCs, they generate naïve cells and restore
the immune system [44]. In addition, HSCs may integrate into
the existing tissues and differentiate into other types of cells
[42]. MSCs may exert its action by immunoregulation [43]. To
be more exciting, Sanchez et al. [45] have shown for the first
time that specific inhibition of SMAD-2/3 signaling pathway
in hESCs facilitates the conversion of hESCs into multipotent
MSCs with fully immunosuppressive and anti-inflammatory
properties in vivo, opening up new avenues for future clin-
ical applications of MSCs. Information on homing and dif-
ferentiation of transplanted stem cells in the injured intestines
are rapidly accumulating. In indomethacin (IDM)-treated rats,
Qu et al. [46] found that transplanted BM-MSCs labeled with
PKH26 resided in the injured intestinal areas, mainly in the
crypts and villi. Surprisingly, cotransplanted stem cells
expressed Lgr-5, a marker of intestinal stem cells (ISCs) two
weeks after cell transfusion [46,47], which indicated that
transplanted stem cells are capable of migrating to the
damaged tissue and further transdifferentiate into ISCs to
restore epithelium function.
While a large number of clinical trials have been
completed or underway, there is a lack of strong evidence of
their effectiveness and safety. Some experts pointed out that
autologous transplantation may put patients at a risk of
receiving the genetically defective immune cells, while allo-
geneic transplantation has a potential to cause myeloablation
[35]. Moreover, recent studies stated that cultured MSC mayIntervention Enrollment
t recruiting Two groups: ASCs, placebo 208
t recruiting Three groups: Placebo High-dose ASCs
Low-dose ASCs
270
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chronic inflammatory environment. Yasuhiro et al. [48] first
demonstrated that MSCs secreted IL-7 and play a pathological
role in IBD by forming the niche for colitogenic CD4 memory
T cells in bone marrow. More researches are needed to further
understand the mechanisms of stem cells before they enter
clinical application. We still do not know what kind of stem
cells is best for CD. In addition to HSCs and MSCs, amniotic
fluid stem cells have been used and the results were encour-
aging [49]. IFN-g-treated human amniotic fluid stem cells
could inhibit T-cell proliferation and increase CD4(þ)
CD25(þ) FOXP3(þ) regulatory T cells. In vivo, IFN-g-
treated human amniotic fluid stem cells were capable of
immunoregulatory function, promoting allograft survival in a
mouse model of allogeneic skin transplantation. Thus, amni-
otic fluid stem cells may be a new source of stem cells for
immunotherapy.
There exit several limitations of the review. First, the
number of included studies was small and none of these trials
were RCT. Second, most of the trials enrolled a few patients.
In one trial with 200 patients enrolled, there was no greater
improvement in patients receiving ASCs and fibrin glue
compared to those receiving fibrin glue alone. Third, quanti-
tative data analyses could not be performed due to heteroge-
neity in designing, classifications of fistulas, treatment and the
duration of follow-up.
5. Conclusion
Stem cell therapy is a field that has developed considerably
in the past decade. Currently available clinical data indicates
that stem cell therapy for CD is very promising. In spite of the
huge accomplishments, stem cell-based therapy is still in its
infancy. There are only 2 ongoing Phase III trials using stem
cells for the treatment of CD (Table 5). However, there is a
long way to go before they are officially approved to be used
for CD. Further large randomized trials are warranted. Enor-
mous advances are needed to bridge the translational gap
between the benchtop researches and clinical applications of
stem cells for CD.
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